Un­der pres­sure from copy­cats, Roche sues Pfiz­er over Her­ceptin ri­val

As biosim­i­lar com­pe­ti­tion puts a squeeze on Roche’s rev­enue, the com­pa­ny is launch­ing a le­gal bat­tle against Pfiz­er and its copy­cat ver­sion of Her­ceptin, Roche’s breast can­cer drug, in hopes to slow or squash a ri­val med­i­cine.

Roche’s Genen­tech busi­ness is al­leg­ing that Pfiz­er’s $PFE copy­cat, called PF-05280014, in­fringes on 40 of Roche’s patents. In the suit, the Swiss phar­ma gi­ant is ask­ing for com­pen­sa­tion on lost sales on Her­ceptin, should the copy­cat get ap­proval be­fore Roche’s patents ex­pire.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.